Twice-daily doses of a Stanford-built molecule called TCIP3 erased human lymphoma tumors implanted in mice within 11 days, while untreated tumors stayed. Graduate student Meredith Nix, a lead author of the work, put it plainly: “By 11 days, the tumors that had been treated with TCIP3 were completely gone.” The molecule works by taking a protein that keeps lymphoma alive and redirecting it to switch on the genes that make a cancer cell die.
Gerald Crabtree, a Stanford pathologist and developmental biologist who is a senior author, described the aim as “trying to essentially fight cancer with its cause.” The idea is to leave the cancer’s own engine running and point it at a different job, instead of simply shutting the engine down.
BCL6, the protein that keeps lymphoma cells alive
The target is BCL6, which Stanford Medicine’s news release on the study identifies as a driver of diffuse large B-cell lymphoma. In healthy immune cells BCL6 acts briefly, silencing genes that would otherwise halt growth or trigger cell death. In lymphoma it stays switched on, and the death genes stay quiet.
Diffuse large B-cell lymphoma is “the most common type of non-Hodgkin lymphoma,” according to the National Cancer Institute, and it grows quickly, often starting in the lymph nodes. Current BCL6-directed drugs either block the protein or degrade it. Nix said TCIP3 goes further because it is also “actively driving the expression of these cell death genes,” so the cell is pushed toward death instead of merely released from a brake.
TCIP3 and the two-headed design
TCIP3 is a bivalent molecule built on the principle of chemically induced proximity, in which a small molecule pulls together two proteins that rarely meet. One end grips BCL6. The other grips P300 or CBP, a pair of enzymes that attach acetyl tags to proteins. Those tags do two jobs at once. Acetylation on BCL6 disables its ability to silence death genes, and acetylation on nearby histones loosens the packaging of DNA so that transcription factors can reach those same genes and turn them on. The protein that once held the brakes on cell death ends up pressing the accelerator.
Sai Gourisankar, a postdoctoral scholar and co-lead author, said in Stanford Report that “TCIP3 acts as a kind of molecular glue, anchoring these proteins together.” X-ray crystallography showed that BCL6 and the enzymes made unplanned contacts once TCIP3 bridged them. The chemists then stiffened the molecule’s linker to preserve those contacts, which made the compound more potent. The work involved Stephen Hinshaw at Stanford and Michael Green at MD Anderson Cancer Center as senior authors alongside Crabtree and Nathanael Gray.
The 11-day mouse result and its limits
In lab-grown lymphoma cells, TCIP3 killed at very low concentrations. The animal test used mice carrying tumors grown from human lymphoma cells. Dosed twice a day, the treated tumors were gone by day 11, per ecancer’s account of the paper, which also reports no obvious toxicity in the mice and no rise in inflammatory signals in their blood. TCIP3 also wiped out germinal centers, the clusters of fast-dividing immune cells that lean heavily on BCL6. The team sees a possible role in autoimmune conditions such as rheumatoid arthritis and myasthenia gravis, though Stanford states plainly that this has not been tested.
The sources read for this article do not give the number of mice, the doses or the specific cell lines, and those details sit in the paper, titled “A bivalent molecular glue linking lysine acetyltransferases to oncogene-induced cell death,” in Cell (volume 189, issue 18). The paper went online July 20, 2026; the ScienceDaily write-up that circulated in October is a repost of the Stanford release dated Aug. 19.
Distance from the clinic, and who stands to gain
Stanford says TCIP3 is not yet ready for use in people. The molecule needs more chemical refinement and testing in additional animal species before a human trial can be considered, and a result in mice with implanted tumors does not settle how a drug behaves in patients with established disease. The disclosures matter too. Crabtree is a founder and scientific advisor of Shenandoah Therapeutics, which holds a Stanford license for the TCIP technology, and Gray is a founder, advisor and board member of the company. Funding came from the National Institutes of Health, the Howard Hughes Medical Institute and several foundations, and the AI drug discovery platform Deep Origin collaborated on the work.
Nix said the approach “could be a powerful approach to tackling other cell death repressors,” and the team is now searching for other cancer-driving proteins that could be rewired the same way. Another repressor responding as BCL6 did would be the first evidence that the design generalizes, and no such result has been reported.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- Two passengers died at an Ohio toll plaza, and the NTSB now wants the cash lanes shut
- Long use of a common prostate pill is tied to a higher chance of glaucoma
- Ford is recalling 223,472 F-150 pickups because the fuel tank can leak or detach
- Hybrids have 15% fewer problems than gas cars, while EVs and plug-in hybrids have about 80% more, Consumer Reports finds
